Medtronic, Inc.

Medtronic Ardian Luxembourg S.a.r.l.

Medtronic Ireland Manufacturing Unlimited Company

Douglas A Hettrick

Li Wang

Shantanu Sarkar

Todd M Zielinski

Eduardo N Warman

Yong Kyun Cho

Todd Jon Sheldon

Paul John Coates

Paul D Ziegler

Scott R Stanslaski

Robert A Betzold

David E Euler

Robert W Stadler

Xusheng Zhang

Avram Scheiner

David L Thompson

Mark T Stewart

Paul T Rothstein

Katherine H Anderson

H Toby Markowitz

Tommy Dean Bennett

John E Burnes

David E Francischelli

Michael O Sweeney

Paul A Belk

Martin Terry Rothman

Kevin T Ousdigian

Mattias Rouw

Robert Melder

Paul A Sobotka

Rahul Mehra

Kenneth C Gardeski

Mark L Brown

Li Ping Wang

Vinod Sharma

Phillip C Falkner

Thomas J Mullen

William J Combs

Paul Gordon Krause

Michael R S Hill

Teresa A Whitman

Raja N Ghanem

Steven C Christian

Roderick E Briscoe

Michael R Ujhelyi

John C Rueter

Christopher P Olig

Gabriel Lazarus

Julie Trudel

Marcia Gallagher

David E Ritscher

Sameh Sowelam

Jodi L Redemske

Abhijeet Dubhashi

Sean Salmon

Kristin L Myers

Stefan Holzer

Helmut Puererfellner

Guo Xu

Kevin P Vincent

Tom Dean Bennett

Robert T Taepke

Lawrence J Mulligan

Trent M Fischer

Daniel Robert Kaiser

David A Igel

Stefan Stoyanov Tunev

Kevin A Wanasek

David J S Kim

Alison Lutterman

Melissa Rhodes

Charles P Sperling

Sandeep S Brar

Stefan S Tunev

Denise Dirnberger

Martin Fahy

Holly S Vitense

Mark Choi

Leonard H Leuer

Shailesh K V Musley

Shailesh Kumar V Musley

Anne M Gillis

Marie T Steinbrink

Charles E Distad

Amber L Jaeger

Nicole M Campbell

Jacqueline Mittelstadt

Michael Bohm

Felix Mahfoud

Venmathi Gunasekaran

Todd M Zielinksi

Kevin P Knox

Donald J Hefner

Melissa M Rhodes

Julia Trudel

Tomas P Daigle

Daniel C Haeg

Philip C Falkner

Systems and methods for performing and assessing neuromodulation therapy are disclosed herein. One method for assessing the efficacy of neuromodulation therapy includes positioning a neuromodulation catheter at a target site within a renal blood vessel of a human patient and delivering neuromodulation energy at the target site with the neuromodulation catheter. The method can further include obtaining a measurement related to a blood flow rate through the renal blood vessel via the neuromodulation catheter. The measurement can be compared to a baseline measurement related to the blood flow rate through the renal blood vessel to assess the efficacy of the neuromodulation therapy. In some embodiments, the baseline and post-neuromodulation measurements are obtained by injecting an indicator fluid into the renal blood vessel upstream of the target site and detecting a transient change in vessel impedance caused by the indicator fluid.

Systems and methods for assessing efficacy of renal neuromodulation therapy

Systems and methods for assessing sympathetic nervous system (SNS) tone for renal neuromodulation therapy are disclosed herein. A system configured in accordance with embodiments of the present technology can include, for example, a detector attached to or implanted in a patient and a receiver communicatively coupled to the detector. The detector can measure cardiac data and the receiver and/or a device communicatively coupled thereto can analyze the cardiac data to provide one or more SNS tone indicators. The SNS tone indicators can be used to determine whether a patient will be responsive to a neuromodulation therapy and/or whether a neuromodulation therapy was effective.

Systems and methods for assessing sympathetic nervous system tone for renal neuromodulation therapy

Methods for treating depression and for reducing a risk associated with developing depression in patients via therapeutic renal neuromodulation and associated systems are disclosed herein. Sympathetic nerve activity can contribute to several cellular and physiological conditions associated with depression as well as an increased risk of developing depression. One aspect of the present technology is directed to methods for improving a patient's calculated risk score corresponding to a depression status in the patient. Other aspects are directed to reducing a likelihood of developing depression in patients presenting one or more depression risk factors. Renal sympathetic nerve activity can be attenuated to improve a patient's depression status or risk of developing depression. The attenuation can be achieved, for example, using an intravascularly positioned catheter carrying a therapeutic assembly configured to use, e.g., electrically-induced, thermally-induced, and/or chemically-induced approaches to modulate the renal sympathetic nerve.

Methods for treating depression in patients via renal neuromodulation

Systems and methods for performing, assessing, and adjusting neuromodulation therapy are disclosed herein. One method for assessing the likely efficacy of neuromodulation therapy includes positioning a neuromodulation catheter at a target site within a renal blood vessel of a human patient and obtaining a measurement related to a diameter of the renal blood vessel via the neuromodulation catheter. The method can further include determining a diameter of the renal blood vessel at or near the target site based on the measurement. In some embodiments, (i) one or more parameters of neuromodulation energy to be delivered to the renal blood vessel can be adjusted based on the determined diameter and/or (ii) the neuromodulation catheter may be repositioned within the renal blood vessel.

Systems, devices, and methods for assessing efficacy of renal neuromodulation therapy

Example systems and techniques for denervation, for example, renal denervation. In some examples, a processor determines one or more tissue characteristics of tissue proximate a target nerve and a blood vessel. The processor may generate, based on the one or more tissue characteristics, an estimated volume of influence of denervation therapy delivered by a therapy delivery device disposed within the blood vessel. The processor may generate a graphical user interface including a graphical representation of the tissue proximate the target nerve and the blood vessel and a graphical representation of the estimated volume of influence.

Denervation therapy

Systems and methods for evaluating neuromodulation via hemodynamic responses are disclosed herein. A system configured in accordance with embodiments of the present technology can include, for example, a neuromodulation catheter comprising an elongated shaft having a distal portion, and a plurality of electrodes spaced along a distal portion. The system can further include a controller communicatively coupled to the electrodes. The controller can be configured to apply first and second stimuli at and/or proximate to a target site within a blood vessel before and after delivering neuromodulation energy to the target site, and detect, via at least one of the electrodes, vessel impedance resulting from the first and second stimuli to determine a baseline impedance and a post-neuromodulation impedance. The controller can further be configured to assess the efficacy of the neuromodulation based, at least in part, on a comparison of the baseline impedance and the post-neuromodulation impedance.

Systems and methods for evaluating neuromodulation therapy via hemodynamic responses

Methods for treating anxiety disorders and for reducing a risk associated with developing an anxiety disorder in patients via therapeutic renal neuromodulation and associated systems are disclosed herein. Sympathetic nerve activity can contribute to several cellular and physiological conditions associated with anxiety disorders as well as an increased risk of developing an anxiety disorder. One aspect of the present technology is directed to methods for improving a patient's calculated risk score corresponding to an anxiety disorder status in the patient. Other aspects are directed to reducing a likelihood of developing an anxiety disorder in patients presenting one or more anxiety disorder risk factors. Renal sympathetic nerve activity can be attenuated to improve a patient's anxiety disorder status or risk of developing an anxiety disorder. The attenuation can be achieved, for example, using an intravascularly positioned catheter carrying a therapeutic assembly configured to use, e.g., electrically-induced, thermally-induced, and/or chemically-induced approaches to modulate the renal sympathetic nerve.

Methods for treating anxiety disorders in patients via renal neuromodulation

Methods for treating post-traumatic stress disorder (PTSD) and/or for reducing a risk associated with developing PTSD in patients via therapeutic renal neuromodulation and associated systems are disclosed herein. Sympathetic nerve activity can contribute to several cellular and physiological conditions associated with PTSD as well as an increased risk of developing PTSD following a traumatic event. One aspect of the present technology is directed to methods for improving a patient's calculated risk score corresponding to a PTSD status in the patient. Other aspects are directed to reducing a likelihood of developing PTSD in patients presenting one or more PTSD risk factors. Renal sympathetic nerve activity can be attenuated to improve a patient's PTSD status or risk of developing PTSD. The attenuation can be achieved, for example, using an intravascularly positioned catheter carrying a therapeutic assembly configured to use, e.g., electrically-induced, thermally-induced, and/or chemically-induced approaches to modulate the renal sympathetic nerve.

Methods for treating post-traumatic stress disorder in patients via renal neuromodulation

Systems and methods for measuring the magnetic fields generated by renal nerves before and/or after neuromodulation therapy are disclosed herein. One method for measuring the magnetic field of target nerves during a neuromodulation procedure includes positioning a neuromodulation catheter at a target site within a renal blood vessel of a human patient near the target nerves, and detecting a measurement of the magnetic field generated by the target nerves. The method can further include determining, based on the measurement of the magnetic field, a location of the target nerves, a location of ablation at the target nerves, and/or a percentage the target nerves were ablated by delivered neuromodulation energy.

Systems, devices, and methods for evaluating neuromodulation therapy via detection of magnetic fields

Methods for treating eating disorders and for reducing a risk associated with developing an eating disorder in patients via therapeutic renal neuromodulation and associated systems. Renal sympathetic nerve activity can be attenuated to improve a patient's eating disorder status or risk of developing an eating disorder. The attenuation can be achieved, for example, using an intravascularly positioned catheter carrying a therapeutic assembly configured to modulate the renal sympathetic nerve.

Methods for treating eating disorders in patients via renal neuromodulation

Systems and methods for neuromodulation therapy are disclosed herein. A method in accordance with embodiments of the present technology can include, for example, positioning a plurality of reference electrodes at the skin of a human patient and intravascularly positioning a plurality of ablation electrodes within a blood vessel lumen at a treatment site. The method can include obtaining impedance measurements between different combinations of the reference electrodes and the ablation electrodes and, based on the impedance measurements, identifying two or more electrode groups for treatment, where at least two of the electrode groups include a different one of the reference electrodes and a different one of the ablation electrodes.

Systems, devices, and associated methods for neuromodulation with enhanced nerve targeting

Techniques for transmitting diagnostic information stored in an implantable medical device (IMD) based on patient hospitalization are described. For example, the IMD may transmit higher resolution diagnostic information to a clinician and/or an external device during a hospitalization period to aid the clinician in evaluating heart failure treatment and when discharge is proper. This higher resolution diagnostic information may include one or more patient metrics automatically generated and transmitted by the IMD at least once every two hours. During a post-hospitalization period, the IMD may transmit lower resolution diagnostic information to a clinician that indicates a risk level of re-hospitalization. The lower resolution diagnostic information may include the risk level and/or patient metrics once a day, for example. In this manner, the IMD transmitted diagnostic information may be tailored to the specific heart failure monitoring needed by the patient.

Heart failure monitoring

Methods for treating hypertension and associated systems and methods are disclosed herein. One aspect of the present technology, for example, is directed to methods for therapeutic renal neuromodulation that partially inhibit sympathetic neural activity in renal nerves proximate a renal blood vessel of a human patient having a 24-hour heart rate at or above a median heart rate for a population of hypertensive patients. This reduction in sympathetic neural activity is expected to therapeutically treat one or more conditions associated with hypertension of the patient. Renal sympathetic nerve activity can be modulated, for example, using an intravascularly positioned catheter carrying a neuromodulation assembly, e.g., a neuromodulation assembly configured to use electrically-induced, thermally-induced, and/or chemically-induced approaches to modulate the renal nerves.

Methods for treating patients with catheter-based renal neuromodulation

Growing community of inventors

Blaine, MN, United States of America

Douglas A Hettrick